Molecular Partners Ag (MOLN) — SEC Filings

Overview

Molecular Partners Ag (MOLN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Mar 30, 2026: Molecular Partners AG filed a 6-K report on March 30, 2026, for the period ending March 31, 2026. The filing includes a press release (EX-99.1) and other documents related to its operations. The company is involved in Biological Products, excluding Diagnostic Substances.

Sentiment Summary

Across 24 filings, the sentiment breakdown is: 2 bullish, 21 neutral, 1 mixed. The dominant filing sentiment for Molecular Partners Ag is neutral.

Filing Type Overview

Molecular Partners Ag (MOLN) has filed 21 6-K, 2 20-F, 1 SC 13D/A with the SEC between Jan 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (24)

• Molecular Partners AG Files 6-K Report — 6-K · Mar 30, 2026 Risk: low
  Molecular Partners AG filed a 6-K report on March 30, 2026, for the period ending March 31, 2026. The filing includes a press release (EX-99.1) and other docume
• 6-K Filing — 6-K · Dec 8, 2025
• 6-K Filing — 6-K · Nov 12, 2025
• Molecular Partners AG Files Q3 2025 Financials — 6-K · Oct 30, 2025 Risk: low
  Molecular Partners AG filed a Form 6-K on October 30, 2025, to furnish a press release and unaudited condensed consolidated interim financial statements for the
• Molecular Partners AG Files 6-K with H1 2025 Financials — 6-K · Aug 25, 2025 Risk: low
  Molecular Partners AG filed a 6-K report on August 25, 2025, for the period ending June 30, 2025. The filing includes financial data for the first half of 2025
• Molecular Partners AG Files 6-K with Press Release — 6-K · Jun 12, 2025 Risk: low
  Molecular Partners AG filed a Form 6-K on June 12, 2025, to furnish a press release issued on June 10, 2025. This filing incorporates the press release by refer
• Molecular Partners AG Files 6-K with Financials and Press Release — 6-K · May 15, 2025 Risk: low
  Molecular Partners AG filed a Form 6-K on May 15, 2025, to furnish a press release and unaudited condensed consolidated interim financial statements for the thr
• Molecular Partners AG Reports 2025 AGM Results — 6-K · Apr 29, 2025 Risk: low
  Molecular Partners AG held its 2025 Annual General Meeting on April 16, 2025, in Schlieren, Switzerland. The results of this meeting are now available on the co
• Molecular Partners AG Files March 2025 6-K Report — 6-K · Mar 6, 2025 Risk: low
  Molecular Partners AG, a Swiss biotechnology company, filed a Form 6-K on March 6, 2025. This report is for the month of March 2025 and indicates the company fi
• Molecular Partners AG Files 2024 Annual Report — 20-F · Mar 6, 2025 Risk: medium
  Molecular Partners AG filed its 20-F for the fiscal year ending December 31, 2024. The filing provides a comprehensive overview of the company's financial posit
• Molecular Partners AG Files Routine 6-K Disclosure — 6-K · Jan 13, 2025 Risk: low
  Molecular Partners AG filed a Form 6-K on January 13, 2025, to report its status as a foreign private issuer. The company, incorporated in Switzerland, is requi
• Molecular Partners AG Files 6-K with Financials — 6-K · Oct 31, 2024 Risk: low
  Molecular Partners AG filed a Form 6-K on October 31, 2024, to furnish a press release and unaudited condensed consolidated interim financial statements for the
• BVF Partners Amends Stake in Molecular Partners AG — SC 13D/A · Oct 29, 2024 Risk: medium
  BVF Partners L.P. has amended its Schedule 13D filing regarding Molecular Partners AG as of October 29, 2024. The filing indicates a change in beneficial owners
• Molecular Partners AG Announces Underwritten Offering — 6-K · Oct 28, 2024 Risk: medium
  On October 24, 2024, Molecular Partners AG entered into an underwriting agreement with Leerink Partners LLC and TD Securities (USA) LLC for an underwritten regi
• Molecular Partners AG: Novartis Deal & MP0712 Data Presented — 6-K · Oct 22, 2024 Risk: medium
  On October 22, 2024, Molecular Partners AG announced the presentation of preclinical data for MP0712, a Radio-DARPin Therapeutic (RDT), at the European Associat
• Molecular Partners AG Files 6-K for Q2 2024 — 6-K · Aug 26, 2024 Risk: low
  Molecular Partners AG filed a 6-K report for the period ending June 30, 2024. The filing provides financial information and details related to the company's ope
• Molecular Partners AG Files 6-K, Incorporates Press Release — 6-K · Jun 14, 2024 Risk: low
  On June 14, 2024, Molecular Partners AG filed a Form 6-K to report the issuance of a press release. This press release is incorporated by reference into their e
• Molecular Partners AG Files 6-K Announcing Press Release — 6-K · Jun 11, 2024 Risk: low
  On June 11, 2024, Molecular Partners AG filed a Form 6-K, announcing the issuance of a press release dated the same day. This press release is attached as Exhib
• Molecular Partners AG Files 6-K with June 1 Press Release — 6-K · Jun 3, 2024 Risk: low
  Molecular Partners AG filed a Form 6-K on June 3, 2024, to report a press release issued on June 1, 2024. The filing incorporates this press release by referenc
• Molecular Partners AG Files 6-K with Q1 2024 Financials — 6-K · May 16, 2024 Risk: low
  Molecular Partners AG filed a Form 6-K on May 16, 2024, to furnish a press release and unaudited condensed consolidated interim financial statements for the thr
• Molecular Partners AG Files 6-K, Attaches Press Release — 6-K · Mar 26, 2024 Risk: low
  Molecular Partners AG announced on March 26, 2024, that it has issued a press release. This press release is attached as Exhibit 99.1 to the Form 6-K filing and
• Molecular Partners AG Files 20-F Annual Report for Fiscal Year 2023 — 20-F · Mar 14, 2024 Risk: medium
  MOLECULAR PARTNERS AG (MOLN) filed a Foreign Annual Report (20-F) with the SEC on March 14, 2024. Molecular Partners AG filed its 20-F annual report for the fis
• Molecular Partners Updates on MP0533, RDT, & New Switch-DARPin Program — 6-K · Jan 8, 2024
  Molecular Partners AG announced updates at the 42nd Annual J.P. Morgan Healthcare Conference on January 7, 2024. Key updates include their tetra-specific T-cell
• Molecular Partners & Orano Med Partner on Radio-DARPin Cancer Therapies — 6-K · Jan 5, 2024
  Molecular Partners AG announced a co-development agreement with Orano Med on January 5, 2024, to create new radio-DARPin therapies for cancer. This collaboratio

Related Companies

MPWR · MPRS · MPLR · NVS · MPTL

Frequently Asked Questions